Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor

Audrey Clapéron, Martine Mergey, Lynda Aoudjehane, Thanh Huong Nguyen Ho‐Bouldoires, Dominique Wendum, Aurélie Prignon, Fatiha Merabtene, Delphine Firrincieli, Christèle Desbois‐Mouthon, Olivier Scatton, Filomena Conti, Chantal Housset, Laura Fouassier – 20 June 2013 – Intrahepatic cholangiocarcinoma (CCA) is characterized by an abundant desmoplastic environment.

Epigenetic silencing of DACH1 induces loss of transforming growth factor‐β1 antiproliferative response in human hepatocellular carcinoma

Hongbin Zhu, Kongming Wu, Wenji Yan, Ling Hu, Jing Yuan, Yan Dong, Yazhuo Li, Kunyu Jing, Yunsheng Yang, Mingzhou Guo – 20 June 2013 – Human dachshund homolog 1 (DACH1) is a major component of the Retinal Determination Gene Network (RDGN) and functions as a tumor suppressor. However, the regulation of DACH1 expression and its function in hepatocellular carcinoma (HCC) remain unclear. In this study, epigenetic changes of DACH1 were analyzed in HCC cell lines and primary cancers.

Growth and development of a new subspecialty: Pediatric hepatology

William F. Balistreri – 20 June 2013 – Several major forces converged to catalyze the formal emergence of a body of knowledge and an organized focus on disorders of the liver in early life. Attendant to the development of a focused clinical subspecialty the pace of patient‐ and laboratory‐based research in the field quickened in parallel to decipher the consequences of genetic or metabolic aberrations on immature liver structure and function.

Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design

Maria Reig, Jordi Rimola, Ferran Torres, Anna Darnell, Carlos Rodriguez‐Lope, Alejandro Forner, Neus LLarch, José Ríos, Carmen Ayuso, Jordi Bruix – 20 June 2013 – Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. Thus, time to tumor progression (TTP) is used to capture benefits of novel molecular agents, but proof of its surrogacy with survival is lacking.

Long‐term deleterious effects of aortohepatic conduits in primary liver transplantation: Proceed with caution

Taizo Hibi, Seigo Nishida, David M. Levi, Daisuke Sugiyama, Kyota Fukazawa, Akin Tekin, Ji Fan, Gennaro Selvaggi, Phillip Ruiz, Andreas G. Tzakis – 19 June 2013 – Aortohepatic conduits provide a vital alternative for graft arterialization during liver transplantation. Conflicting results exist with respect to the rates of comorbidities, and long‐term survival data on primary grafts are lacking.

Decadal analysis of deceased organ donation in Spain and the United States linking an increased donation rate and the utilization of older donors

Jeff Halldorson, John Paul Roberts – 19 June 2013 – After the foundation of the National Transplant Organization, Spanish rates of deceased donor donation rapidly outpaced US growth over the decade from 1989 to 1999. An analysis of the following decade, 1999‐2009, demonstrated a markedly flattened growth curve for Spanish deceased donor organ procurement, which increased only 2.4% from 33.6 to 34.4 donors per million population (pmp). In comparison, over the same decade in the United States, the rate of deceased donation increased from 20.9 to 26.3 donors pmp (25.8%).

Subscribe to